Sequus, Sheffield Medical Technologies Inc. deal

SEQU exercised its option to license SHM's liposome-CD4 technology as a potential therapy for HIV and AIDS, for an undisclosed signing fee payable in SEQU common stock, plus milestones and royalties. SEQU has 26.9 million shares outstanding prior to the agreement. ...